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Objectives The aim of this study was to investigate the relationship between lipid and nonlipid biomarker levels achieved
during statin therapy and the incidence of major cardiovascular events (MCVEs) in patients with stable coronary
heart disease (CHD).
Background Several plasma nonlipid biomarkers have been shown to predict MCVEs in population studies.
Methods This is a nested case-control study in the TNT (Treating to New Targets) study population, a randomized trial that
compared the efficacy of high- (80 mg) versus low-dose (10 mg) atorvastatin for the secondary prevention of
CHD. Fasting plasma levels of standard lipids and of 18 nonlipid biomarkers were obtained after an 8-week
run-in period on atorvastatin 10 mg and again 1 year after being randomized to 10 or 80 mg atorvastatin in 507
patients who experienced MCVEs during the 4.9 years of study follow-up and in 1,020 control subjects. An MCVE
was defined as CHD death; nonfatal, non–procedure-related myocardial infarction; resuscitated cardiac arrest; or
fatal or nonfatal stroke.
Results Low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides were all predictive of
recurrent MCVEs (p  0.009). Concentrations of many of the 18 nonlipid biomarkers were lowered by atorvasta-
tin therapy (independent of dose). However, almost none of the nonlipid biomarker levels, whether measured
after the 8-week run-in period or after 1 year of treatment with 10 or 80 mg atorvastatin, were predictive of re-
current MCVEs.
Conclusions In patients with stable CHD, atorvastatin improved plasma levels of an expanded panel of nonlipid biomarkers.
However, independently of atorvastatin dose, the achieved levels of the vast majority of nonlipid biomarkers did
not predict MCVEs. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below
Minimum Target Levels [TNT]; NCT00327691) (J Am Coll Cardiol 2011;57:63–9) © 2011 by the American Col-
lege of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.052
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Athe concentration of nonlipid bi-
omarkers such as hsCRP should
be included in algorithms de-
signed to predict cardiovascular
outcomes and to measure the
efficacy of statin treatment (6).
However, there are inconsisten-
cies, with some studies finding
that levels of nonlipid biomarkers
have minimal predictive power
beyond that of established CHD
risk factors (7–9). We further
address this issue by investigating
how the concentrations of plasma
lipids and nonlipid biomarkers re-
late to cardiovascular events in the
TNT (Treating to New Targets)
study.
ethods
tudy design. The study protocol and outcome measures
or the TNT study have been published previously (10). In
rief, patients with clinically manifest CHD commenced 8
eeks of open-label treatment with atorvastatin 10 mg/day.
fter this run-in period, 10,001 patients with low-density
ipoprotein cholesterol (LDL-C) levels3.4 mmol/l (130
g/dl) were randomized in a double-blind design to therapy
ith either 10 mg or 80 mg of atorvastatin/day. Patients
ere followed for a median of 4.9 years. The primary end
oint was the time to the first occurrence of a major
ardiovascular event (MCVE), defined as CHD death;
onfatal, non-procedure-related myocardial infarction; re-
uscitated cardiac arrest; or fatal or nonfatal stroke. A full
escription of the nested case-control study population and
iomarker analyses is presented in the Online Appendix (see
lso Table 1).
tatistical methods. Patient characteristics at randomiza-
ion were compared between treatment groups of the main
tudy and treatment groups of this substudy with a chi-
quare test for categorical variables and a Wilcoxon rank
um test for continuous variables. Similarly, characteristics
f substudy patients at time of randomization were com-
ared between those who did and those who did not
xperience a cardiovascular event during the study follow-
p. Changes in biomarkers were tested with a signed rank
est and compared between treatment groups with a Wil-
oxon rank sum test. The association between on-treatment
ipids and biomarker levels (at time of randomization and at
year) and primary end point was assessed with Cox
roportional hazards after adjustment for age, sex, and
reatment effect, with time to primary end point as the
ependent variable for all patients and for patients within
ach treatment group. Treatment by biomarker interaction
as examined separately in the same model with the
Abbreviations
and Acronyms
CHD  coronary heart
disease
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MCVE  major
cardiovascular event
NT-proBNP  N-terminal
fragment of pro-B-type
natriuretic peptide
RE
TRddition of interaction term. Logistic regression was also
C
ased to confirm the findings observed with Cox propor-
ional hazards. Independent variables included age, sex,
reatment effect, and the log2 transformed biomarker level.
esults
atient population. Characteristics of patients in this sub-
tudy were similar to those in the total TNT population
Table 2). Characteristics of patients in the biomarker
ubgroup who experienced an MCVE and those who did
ot are also shown in Table 2 for the classical CHD risk
actors and in Table 3 for the nonlipid biomarkers. The
atients randomly selected as control subjects had similar
haracteristics compared with the rest of patients who did
ot have a clinical event (p  0.10). At the time of
andomization all participants had been taking atorvastatin
t a dose of 10 mg/day for at least 8 weeks.
elationships of MCVEs to biomarker levels measured
t time of randomization. Table 4 shows the relationship
etween standard lipids and nonlipid biomarkers and risk of
CVE with Cox proportional hazards. In this analysis of
he combined 10- and 80-mg atorvastatin groups, the
oncentrations of LDL-C, triglycerides, and high-density
ipoprotein cholesterol (HDL-C) measured at randomiza-
ion were all predictive of MCVEs. In contrast, almost none
f the nonlipid biomarkers measured at the time of ran-
omization predicted MCVEs. The only exception was
steopontin, with higher levels at randomization associated
ith a significantly lower risk of future MCVE. In addition
o the analysis of the combined 10- and 80-mg atorvastatin
roups, separate analyses were performed for each treatment
roup. These relationships between lipid levels at random-
zation and subsequent MCVEs in the separate treatment
roups were consistent with those observed in the overall
tudy population (Online Table 1). Similar results were
btained with logistic regression (Online Table 2) and upon
xclusion of patients who had experienced fatal or nonfatal
troke during follow-up (Online Table 3).
ffect of treatment on biomarker levels. Significant
hanges from baseline in the levels of all lipids and most
iomarkers Studied in TNTTable 1 Biomarkers Studied in TNT
Pathophysiological Role Biomarkers Analyzed
Systemic inflammation CRP
Macrophage recruitment/activity MCP-1; neopterin; sICAM-1; sVCAM-1
Oxidative stress MPO; Lp-PLA2
Tissue remodeling MMP-9; osteopontin
Platelet/thrombosis sCD40L; Lp(a)
Insulin resistance Insulin; adiponectin; HMW adiponectin;
HMW/total adiponectin (ratio); RAGE
Congestive heart failure NT-proBNP
Kidney function Cystatin C
RP  C-reactive protein; HMW  high molecular weight; Lp(a)  lipoprotein (a); Lp-PLA2 
ipoprotein-associated phospholipase A2; MCP  monocyte chemoattractant protein; MMP 
atrix metalloproteinase; MPO  myeloperoxidase; NT-proBNP  N-terminal fragment of pro–B-
ype natriuretic peptide; RAGE receptor for advanced glycation end products; sCD40L  soluble
CT
EDD40 ligand; sICAM  soluble intercellular adhesion molecule; sVCAM  soluble vascular cell
dhesion molecule; TNT  Treating to New Targets study.
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A
onlipid biomarkers were observed after 1 year in both the
0- and 80-mg atorvastatin groups (Fig. 1). There were no
ignificant differences between the changes observed in the
treatment groups.
elationships between MCVEs and biomarker levels
easured after 1 year of treatment. After 1 year of
reatment with atorvastatin, levels of LDL-C, HDL-C, and
riglycerides remained significantly predictive of subsequent
CVEs in the combined groups and in the 10-mg atorva-
tatin group (Table 5). In the 80-mg atorvastatin group, it
as only the HDL-C measured at 1 year that remained as
significant predictor of MCVEs. Almost none of the
onlipid biomarkers measured after 1 year of treatment were
redictive of MCVEs in either treatment group, in contrast
atients Characteristics at Time of RandomizationTable 2 Patients Characteristics at Ti e of Randomization
Characteristic
Main Study by Treatment
Atorvastatin 10 mg
(n  5,006)
Atorvastatin 80 mg
(n  4,995)
Atorvas
(n
Age (yrs) 60.9 (8.8) 61.2 (8.8) 60
Male (%) 80.8 81.2
Risk factor (%)
Current smoker 13.4 13.4
Hypertension 54.4 53.9
Diabetes 15.0 15.0
Lipids (mg/dl)
LDL-C 98 (18) 98 (17) 9
Total cholesterol 175 (24) 175 (24) 17
Triglycerides 151 (72) 151 (70) 15
HDL-C 47 (11) 47 (11) 4
t the time of randomization, all participants had been taking 10 mg atorvastatin for at least 8 weeks. *T
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol.
on-Lipid Biomarker Levels at Time of RandomizationTable 3 Non-Lipid Biomarker Levels at Ti e of Randomization
Nonlipid Biomarker
Substudy by Treatment
Atorvastatin 10 mg
(n  810)
Atorvastatin 80
(n  717)
Adiponectin (ng/ml) 6,562 (4,821–9,411) 6,593 (4,664–9,
HMW adiponectin (ng/ml) 1,960 (1,180–3,155) 1,929 (1,204–3,
HMW/total adiponectin 0.292 (0.220–0.362) 0.293 (0.229–0.
CRP (mg/l) 1.7 (0.8–4.1) 1.8 (0.8–3.8)
Cystatin C (ng/ml) 779.7 (675.2–924.0) 782.8 (677.8–91
Insulin (U/ml) 12.0 (9.0–17.0) 12.0 (9.0–17.5
Lp-PLA2 (ng/ml) 325.5 (259.5–387.5) 323.0 (265.0–39
Lp(a) (mg/ml) 16 (5–40) 13 (4–40)
MCP-1 (pg/ml) 100 (75–130) 99 (74–133)
MMP-9 (pg/ml) 44,301 (30,679–65,702) 43,619 (29,299–6
MPO (pg/ml) 22,237 (10,719–54,235) 20,993 (10,324–5
Neopterin (ng/ml) 2.9 (2.3–3.6) 2.9 (2.4–3.6)
NT-proBNP (fmol/ml) 514 (407–661) 503 (401–645
Osteopontin (ng/ml) 47.0 (32.2–60.5) 46.4 (33.0–58.
RAGE (pg/ml) 1,330 (1,025–1,831) 1,318 (1,004–1,
sCD40L (pg/ml) 4,033 (1,831–9,472) 3,953 (1,978–9,
sICAM-1 (ng/ml) 142 (108–184) 146 (107–186
sVCAM-1 (ng/ml) 1,052 (0.885–1,275) 1,048 (0.858–1,
RE
Tt the time of randomization, all participants had been taking 10mg atorvastatin for at least 8 weeks. *The
Abbreviations as in Table 1.o the lipid levels. Changes in nonlipid biomarker levels
etween randomization and 1 year did not predict MCVEs
n the total group or in either treatment group (data not
hown). Similar results were obtained with logistic regres-
ion (Online Table 4) and upon exclusion of patients who
ad experienced fatal or nonfatal stroke during follow-up
Online Table 5).
iscussion
his nested case-control substudy of the TNT trial was
esigned to investigate the ability of a number of lipid and
onlipid biomarkers to predict MVCEs in stable, statin-
reated CHD patients. Although the ability of traditional
study by Treatment Substudy by Event
p Value*
0 mg
)
Atorvastatin 80 mg
(n  717)
With Event
(n  507)
Without Event
(n  1,020)
) 61.5 (8.5) 62.6 (8.4) 60.4 (8.7) 0.0001
84.0 82.8 82.9 0.9606
14.1 18.5 11.8 0.0015
54.4 63.5 50.6 0.0001
15.6 23.3 12.1 0.0001
) 97 (17) 100 (17) 96 (17) 0.0001
) 174 (23) 176 (25) 173 (23) 0.0296
) 148 (71) 158 (78) 147 (69) 0.0145
) 47 (11) 45 (10) 48 (11) 0.0001
lue for patients that experienced an event versus those that did not in the biomarker subgroup.
Substudy by Event
p Value*
With Event
(n  507)
Without Event
(n  1,020)
6,212 (4,651–9,338) 6,702 (4,838–9,287) 0.16
1,867 (1,188–2,948) 1,969 (1,184–3,216) 0.26
0.293 (0.224–0.362) 0.292 (0.225–0.367) 0.81
1.8 (0.9–4.0) 1.7 (0.7–3.8) 0.08
789.4 (675.0–934.1) 776.6 (676.9–912.6) 0.51
12.0 (9.0–17.0) 12.0 (9.0–18.0) 0.41
326.0 (264.0–389.0) 324.0 (262.0–389.0) 0.67
13 (4–39) 15 (5–40) 0.36
100 (77–131) 100 (75–131) 0.80
) 43,347 (30,370–70,114) 44,524 (29,861–65,573) 0.69
) 22,077 (11,266–57,689) 21,246 (10,116–56,275) 0.31
2.8 (2.3–3.6) 2.9 (2.4–3.6) 0.48
519 (405–645) 505 (402–652) 0.39
45.2 (29.9–59.2) 47.5 (33.6–59.8) 0.04
1,288 (1,011–1,861) 1,341 (1,018–1,771) 0.84
3,918 (1,844–8,977) 4,024 (1,879–9,987) 0.37
139 (103–185) 145 (110–185) 0.35
1,030 (0.855–1,271) 1,056 (0.885–1,263) 0.48
CT
EDSub
tatin 1
 810
.8 (8.8
82.0
14.0
55.3
15.9
7 (17
4 (24
3 (72
6 (10mg
240)
095)
368)
5.5)
)
1.0)
8,805
7,628
)
7)
761)
566)
)
259)p value for patients that experienced an event versus those that did not in the biomarker subgroup.
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Aipid biomarkers to predict MCVEs was completely consis-ent with observations from a large number of previous
tudies, almost none of the emerging nonlipid biomarkers
redicted the risk of MCVEs in the current analysis, a
nding that seems to contrast with studies conducted in
ndividuals not taking statins in which several of these
onlipid biomarkers have been reported to be independent
redictors of incident MCVEs (11–13). This suggests that,
n statin-treated patients with stable CHD, in contrast to
tandard lipids, nonlipid biomarkers have virtually no pre-
ictive value and should not be used to monitor the efficacy
f statin treatment.
Several studies have shown that statins reduce plasma
evels of markers associated with systemic inflammation,
xidative stress, tissue remodeling, and/or insulin resistance
4,5,14). In the present study—which is one of the most
omprehensive studies on the topic, in terms of sample size
nd number of biomarkers studied—we found that most of
he biomarkers plasma levels improved between the 8-week
un-in period and 1 year. However, our results show that
ncreasing atorvastatin dose to 80 mg did not result in
dditional changes in biomarkers levels. This finding seems
o contrast with other trials performed in patients with
HD, such as the CAP (Comparative Atorvastatin Pleio-
ropic) effect study and the PROVE IT–TIMI 22 (Prava-
tatin or Atorvastatin Evaluation and Infection Therapy–
elationships of MCVEs to Biomarker Levels Measured at Time ofTable 4 Relationships of MCVEs to Biomarker Levels Measured
All Patients
HR* 95% CI p Value H
Lipid biomarker
LDL-C 2.09 1.48–2.95 0.0001 2
HDL-C 0.35 0.26–0.47 0.0001 0
Triglycerides 1.27 1.10–1.46 0.0012 1
Nonlipid biomarker
Adiponectin 0.96 0.87–1.05 0.3280 1
HMW adiponectin 0.98 0.91–1.07 0.6960 1
HMW/total adiponectin 1.01 0.91–1.13 0.8250 1
CRP 1.04 0.99–1.09 0.1090 1
Cystatin C 1.03 0.92–1.16 0.6200 1
Insulin 1.06 0.95–1.17 0.3200 1
Lp-PLA2 0.99 0.80–1.23 0.9450† 1
Lp(a) 0.99 0.94–1.05 0.8070 0
MCP-1 1.02 0.91–1.14 0.7950† 0
MMP-9 0.99 0.91–1.08 0.8110 0
MPO 1.01 0.96–1.06 0.7930 0
Neopterin 1.00 0.85–1.17 0.9590 1
NT-proBNP 1.10 0.95–1.28 0.1850 1
Osteopontin 0.90 0.84–0.97 0.0030 0
RAGE 1.06 0.92–1.22 0.4270† 1
sCD40L 0.98 0.93–1.02 0.3150 1
sICAM-1 0.99 0.87–1.12 0.8360 1
sVCAM-1 1.03 0.86–1.22 0.7570† 1
t the time of randomization, all participants had been taking 10mg atorvastatin for at least 8 week
ffect; †p  0.05 (p  0.02) for treatment by biomarker interaction.
CI  confidence interval; MCVE  major cardiovascular event; other abbreviations as in Tables
RE
Rhrombolysis In Myocardial Infarction 22) study, in which mdose-response effect of statin on CRP levels was observed
80 mg atorvastatin vs. 40 mg pravastatin in the PROVE
T–TIMI 22 trial, and 80 mg atorvastatin vs. 10 mg
torvastatin in the CAP trial) (4,15). Additionally, in the
EVERSAL (Reversal of Atherosclerosis with Aggressive
ipid Lowering) trial, 80 mg atorvastatin provided a 36.4%
ecrease in CRP levels compared with 5.2% for patients
reated with 40 mg pravastatin (16). Our results suggest that
he biomarker that is most influenced by atorvastatin treat-
ent is myeloperoxidase, which plasma levels increased by
0.7% and 25.6% for the 10- and 80-mg atorvastatin
roups, respectively. Such an increase in myeloperoxidase
evels upon statin therapy has already been observed by
euwese et al. (17) in a sample of patients with heterozy-
ous familial hypercholesterolemia treated with either ator-
astatin 80 mg or simvastatin 40 mg. As for the predictive
alue of CRP, our results are not in line with those of the
ROVE IT–TIMI 22 and A to Z (Aggrastat-to-Zocor)
rials, in which plasma levels of CRP did predict cardiovas-
ular disease (CVD) outcomes in statin-treated patients
ith acute coronary syndrome (4,18). However, it should be
oted that, although these study populations were similar in
erms of age, sex, diabetes, and hypertension prevalence as
ell as lipid levels, the proportion of smokers in the TNT
rial was almost twice as low compared with the PROVE
T–TIMI 22 and A to Z study populations. This difference
omizationi e of Randomization
Atorvastatin 10 mg Atorvastatin 80 mg
95% CI p Value HR* 95% CI p Value
1.42–3.64 0.0006 1.90 1.14–3.15 0.0134
0.23–0.55 0.0001 0.33 0.23–0.51 0.0001
1.08–1.59 0.0068 1.21 0.99–1.50 0.0691
0.89–1.22 0.5940 0.91 0.82–1.01 0.0690
0.91–1.14 0.7450 0.94 0.84–1.06 0.3400
0.86–1.17 0.9950 1.03 0.88–1.19 0.7400
1.01–1.14 0.0243 0.99 0.92–1.07 0.8170
0.91–1.24 0.4610 0.99 0.83–1.17 0.8700
0.97–1.29 0.1110 0.96 0.82–1.14 0.6540
0.91–1.61 0.2000 0.77 0.56–1.06 0.1070
0.90–1.04 0.3830 1.02 0.95–1.11 0.5700
0.77–1.06 0.2110 1.15 0.98–1.35 0.0900
0.85–1.12 0.6790 1.00 0.89–1.14 0.9540
0.93–1.06 0.8540 1.02 0.95–1.09 0.5920
0.89–1.36 0.3890 0.89 0.71–1.12 0.3200
0.87–1.31 0.5360 1.15 0.93–1.42 0.2060
0.80–0.97 0.0101 0.92 0.83–1.03 0.1420
1.01–1.46 0.0362 0.88 0.72–1.09 0.2450
0.93–1.06 0.9040 0.95 0.89–1.02 0.1760
0.86–1.23 0.7640 0.95 0.79–1.13 0.5460
0.99–1.72 0.0590 0.88 0.73–1.07 0.1930
ard ratio (HR) associated with doubling the concentration and adjusting for age, sex, and treatment
.
CT
EDRandat T
R*
.27
.36
.31
.04
.02
.00
.07
.06
.12
.21
.97
.90
.97
.99
.10
.07
.88
.22
.00
.03
.31
s. *Hazight explain, at least to a certain extent, the difference
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Aetween CRP levels and cardiovascular outcomes observed
cross these studies.
Elevated plasma levels of inflammatory and oxidative
tress markers are common in individuals with excess
isceral adiposity and insulin resistance (19,20). Visceral
dipocytes as well as the macrophages that infiltrate adipose
issue are major contributors to the plasma levels of many of
he biomarkers we measured, including hsCRP (21,22).
ecause most of the study patients were older, were over-
eight or obese, or already had documented CHD, it is
ighly likely that most had an excess of visceral adipose
% Change in plasma biomarker level
-50 0 50 100 150 200 250
Adiponectin
HMW Adiponectin
HMW Adiponectin/Adiponectin
C-Reactive Protein
Cystatin C
Insulin
Lp-PLA2
Lipoprotein (a)
MCP-1
MMP9
MPO
Neopterin
NT-proBNP
Osteopontin
RAGE
sCD40L
sICAM-1
sVCAM-1
Lipid biomarker
LDL-cholesterol
HDL-cholesterol
Triglycerides
Non-lipid biomarker
Figure 1
Percentage Change in Lipid and
Nonlipid Biomarkers Levels After 1 Year
of Treatment With Atorvastatin 10 or 80 mg
Shown are median (interquartile range). Changes in biomarker levels did not
differ between 10- and 80-mg atorvastatin groups (2-sided Wilcoxon rank sum
test). For each biomarker, the top bar represents changes with 80 mg atorva-
statin, and the bottom bar represents changes with 10 mg atorvastatin. Black
circles represent significant changes from baseline to 1 year (p  0.05 from
signed rank test), and white squares represent nonsignificant changes. HDL-C
 high-density lipoprotein cholesterol; HMW  high molecular weight; LDL-C 
low-density lipoprotein cholesterol; Lp-PLA2  lipoprotein-associated phospho-
lipase A2; MCP  monocyte chemoattractant protein; MPO  myeloperoxi-
dase; NT-proBNP  N-terminal fragment of pro–B-type natriuretic peptide; RAGE
 receptor for advanced glycation end products; sCD40L  soluble CD40
ligand; sICAM  soluble intercellular adhesion molecule; sVCAM  soluble
vascular cell adhesion molecule. ET
Rissue. Although statins have several documented pleiotro- fic effects, they have no effects on either body weight or
ody fat distribution. Thus, even though statins improved
lasma levels of the studied biomarkers, there is no evidence
hat they have an impact on the likely biological sources of
hese biomarkers in the patients included in the TNT study.
his might have had an influence on the observed relation-
hips between biomarker levels and the risk of recurrent
HD. We believe that this analysis of TNT participants
ight have yielded different results if the intervention had
een lifestyle modification instead of statin therapy.
The results of the present study do not question the
elevance of systemic inflammation or inflammatory mark-
rs in the pathophysiology of CVD, for several reasons. We
now from epidemiological studies that: 1) several markers
f inflammation are independent CVD risk factors; and
) initiating lipid-lowering therapy in individuals with
levated biomarker levels (at least hsCRP) brings clinical
enefits (4,5). However, our observations suggest that such
ardiovascular benefits are primarily attributable to the
ffects of statins on lipids rather than nonlipid biomarker
evels. Future trials recording CHD outcomes in patients
aking anti-inflammatory drugs (other than statins) are
ecessary to determine whether targeting inflammation is
seful for CHD prevention (23).
In this case-control study, levels of traditional lipid
iomarkers measured at randomization, when all subjects
ad already been taking 10 mg atorvastatin for at least 8
eeks, were predictive of future MCVEs in the combined
roup as well as in the 10- and 80-mg atorvastatin groups
tudied separately. Because the ability of LDL-C and
DL-C levels at randomization to predict future cardio-
ascular events was similar to what has been reported in
any other studies, considerable confidence is provided in
he validity of the approach used in this case-control study.
owever, it should be considered that these analyses were
onfined to patients participating to the TNT trial in whom
dditional informed consent was obtained. For instance,
1.5% of the cases recorded in the TNT cohort were
ncluded in the present analyses, which could have limited
ur power to detect associations between biomarkers and
he risk of MCVE. In the absence of a complete dataset, we
ave used a nested case-control design. Although it could be
rgued that this might have limited the power to detect the
rue predictive value of the biomarkers tested, this type of
esign is increasingly being used to study causal relation-
hips in cohort studies and has been demonstrated to be an
fficient sampling method in well-defined cohorts (24).
ase-control studies are often not based on well-defined
atient populations, making it difficult on occasion to ensure
hat cases and control subjects are a representative sample of
he population under study. In the current analysis, all cases
ere drawn from the well-defined TNT patient population,
ith the control subjects being randomly sampled from this
ame patient population. Also in support of the findings
resented here, the predicted value of the lipid biomarkers
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Areatment) were similar in the samples selected in thisested case-control study and the entire TNT sample set.
hus, results from this biomarker study are highly likely to
e applicable to patients similar to those studied in the TNT
rial. The TNT trial did not include a placebo group,
ecause all participants received active treatments. It was
hus not possible to make comparisons with untreated
atients. As a consequence, it must be emphasized that our
ata should not be interpreted as a negation or a contradic-
ion of the results of studies showing the ability of bio-
arkers to predict MCVEs in other populations or in
symptomatic individuals. Finally, it should be taken into
onsideration that the assays that we have used for the
easurement of CRP and N-terminal fragment of pro–B-
ype natriuretic peptide (NT-proBNP) have not been clin-
cally validated. However, a cross-validation study demon-
trated that the human CVD Panel 2 LINCOplex kit from
illipore (St. Charles, Missouri) (used in the present study)
as highly correlated with the clinically validated Dade
ehring (Deerfield, Illinois) assay (correlation coefficients of
 0.91 for baseline samples [n  150] and r  0.93 for
ear-1 samples [n  116]). As for NT-proBNP, it must be
cknowledged that the assay used in this study (Biomedica,
ienna, Austria) is based on a different principle than the
linically validated assay from Roche Diagnostics (Basel,
witzerland), because the assays recognize different
elationships of MCVEs to Biomarker Levels Measured After 1 YeaTable 5 Relationships of MCVEs to Biomarker Levels Measured
All Patients
HR* 95% CI p Value H
Lipid biomarker
LDL-C 1.43 1.09–1.87 0.0090 1
HDL-C 0.37 0.27–0.49 0.0001 0
Triglycerides 1.28 1.12–1.47 0.0003 1
Nonlipid biomarker
Adiponectin 0.93 0.81–1.08 0.3630 1
HMW adiponectin 0.97 0.88–1.06 0.4660 1
HMW/total adiponectin 1.00 0.87–1.15 0.9770 1
CRP 1.02 0.96–1.08 0.5240 1
Cystatin C 0.95 0.84–1.06 0.3590† 1
Insulin 0.99 0.87–1.13 0.8890 0
Lp-PLA2 1.06 0.82–1.37 0.6610 1
Lp(a) 0.97 0.91–1.03 0.3430 0
MCP-1 1.08 0.94–1.24 0.2860 1
MMP-9 1.00 0.90–1.11 0.9780 1
MPO 0.99 0.93–1.06 0.7860 1
Neopterin 1.12 0.93–1.35 0.2430 1
NT-proBNP 1.02 0.85–1.22 0.8390 1
Osteopontin 1.01 0.91–1.11 0.9080 1
RAGE 1.02 0.87–1.21 0.7850 1
sCD40L 1.03 0.97–1.09 0.3850 1
sICAM-1 1.00 0.85–1.19 0.9870 1
sVCAM-1 0.95 0.76–1.19 0.6700 1
The HR associated with doubling the concentration and adjusting for age, sex, and treatment effe
f follow-up (n  157) were not included in the present analyses.
Abbreviations as in Tables 1, 2, 3, and 4.
RE
TRpitopes/fragments of NT-proBNP. However, even if both assays have been shown to have a comparable ability to
etect the presence of heart failure (25), our results cannot
ompletely rule out the potential presence of a positive
ssociation between NT-proBNP and cardiovascular events
n statin-treated patients.
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